Intellectual disability (ID), formerly known as mental retardation, is characterized by significant limitations in intellectual functioning and adaptive behavior, manifesting before age 18. It affects approximately 2–3% of the population and has a complex etiology involving genetic, environmental, and developmental factors. Among the genetic causes, X-linked intellectual disability (XLID) accounts for a substantial proportion, particularly in male patients. The oligophrenin-1 (OPHN1) gene, located on chromosome Xq12, is one of several genes linked to XLID through Rho GTPase-dependent signaling pathways. Initially described as a cause of non-syndromic XLID, recent studies have revealed that OPHN1 mutations are associated with distinct neuroanatomical features, including cerebellar hypoplasia, ventriculomegaly, and facial dysmorphisms such as strabismus and deep-set eyes.
In this study, we report a three-generation Brazilian family with XLID segregating a novel intragenic deletion in OPHN1. The deletion, identified via high-resolution array CGH, results in an in-frame loss of exon 7 at the transcript level (c.781_891del; r.487_597del). This alteration leads to the removal of 37 conserved amino acids from the N-terminal BAR domain of OPHN1, a region critical for membrane curvature sensing and protein–protein interactions. Despite the structural change, cDNA analysis confirmed that the mutant transcript is stable and undergoes normal splicing, indicating that the mutation does not trigger nonsense-mediated decay or aberrant splicing.
Clinically, affected males exhibited neonatal hypotonia, hyperactivity, instability, intolerance to frustration, and distinctive facial features including prominent nasal root, deep-set eyes, and strabismus.Risdiplam Cancer All affected individuals showed large lateral ventricles, vermis hypoplasia, and cystic dilatation of the cisterna magna on cranial MRI. Notably, hippocampal alterations—including hypoplasia and verticalization—were observed in three affected males, a feature not previously reported in patients with complete loss-of-function OPHN1 mutations. These findings suggest a specific role for the BAR domain in hippocampal development and function, beyond its general involvement in synaptic plasticity.
Carrier females displayed variable phenotypes: the mother (II.2) had severe ID and epilepsy, while her daughter (II.7) was cognitively unaffected despite carrying the deletion.UiO-66-(COOH)2 Cancer EEG recordings in II.7 revealed frontal epileptiform discharges, suggesting subclinical seizure activity. Neuroimaging in carrier females showed periventricular cysts and white matter hyperintensities in the mother and grandmother, but not in the asymptomatic aunt. X-inactivation analysis revealed random patterns in both II.2 and II.7, indicating that phenotypic variability may stem from tissue-specific expression rather than skewed inactivation.
This case represents the first documented in-frame deletion within the BAR domain of OPHN1. The absence of a premature stop codon implies that the mutant protein retains partial functionality, yet its altered structure likely disrupts regulatory mechanisms involving membrane dynamics and Rho GTPase signaling.PMID:35127542 The presence of microhomology at the deletion junction suggests a mechanism of microhomology-mediated break-induced repair (MMBIR), consistent with replication-based genomic rearrangements.
These findings expand our understanding of OPHN1’s functional domains and highlight the importance of the BAR domain in brain development. They also underscore the need for comprehensive neuroimaging and molecular screening in XLID families, especially those presenting with cerebellar abnormalities, seizures, or facial dysmorphisms. Further research into the role of the BAR domain may provide insights into the pathogenesis of cognitive disorders and inform future therapeutic strategies targeting synaptic stability and neural circuitry.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com